Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Mosca

Showing results (211-220 of 377) with videos related to

Pageof 38
Sort By:
Rheumatology (Oxford, England)|August 28, 2012
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?Rossella Reggia, Tamara Ziglioli, Laura Andreoli, et al.
Clinical and Experimental Rheumatology|September 12, 2024
Preferences for diagnostic pathways and treatment choice in systemic lupus erythematosus: a patient-based discrete choice experimentLuca Quartuccio, Matteo Piga, Fabiola Atzeni, et al.
Plos One|January 13, 2021
Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flareDina Zucchi, Chiara Tani, Elena Elefante, et al.
Clinical and Experimental Rheumatology|June 29, 2023
Adherence to therapy in people with rheumatic and musculoskeletal diseases in Italy and the role of the digital health: results of an expert Delphi consensus surveyAnnamaria Iagnocco, Francesco Ciccia, Fabrizio Conti, et al.
Clinical and Experimental Rheumatology|October 18, 2012
Treat-to-target in systemic lupus erythematosus: where are we today?Marta Mosca, Dimitrios T Boumpas, Ian N Bruce, et al.
Journal of Personalized Medicine|July 27, 2024
Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Clinical and Experimental Medicine|March 30, 2024
Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohortStefano Gentileschi, Carla Gaggiano, Arianna Damiani, et al.
Lupus Science & Medicine|October 17, 2023
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for RheumatologyChiara Scirocco, Sara Ferrigno, Laura Andreoli, et al.
Journal of Personalized Medicine|September 28, 2023
ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical PracticeMaurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Clinical and Experimental Rheumatology|August 4, 2017
The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaicNancy Agmon-Levin, Amir Dagan, Yogev Peri, et al.
Pageof 38

Showing results (211-220 of 377) with videos related to

Sort By:
Pageof 38
Rheumatology (Oxford, England)|August 28, 2012
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?Rossella Reggia, Tamara Ziglioli, Laura Andreoli, et al.
Clinical and Experimental Rheumatology|September 12, 2024
Preferences for diagnostic pathways and treatment choice in systemic lupus erythematosus: a patient-based discrete choice experimentLuca Quartuccio, Matteo Piga, Fabiola Atzeni, et al.
Plos One|January 13, 2021
Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flareDina Zucchi, Chiara Tani, Elena Elefante, et al.
Clinical and Experimental Rheumatology|June 29, 2023
Adherence to therapy in people with rheumatic and musculoskeletal diseases in Italy and the role of the digital health: results of an expert Delphi consensus surveyAnnamaria Iagnocco, Francesco Ciccia, Fabrizio Conti, et al.
Clinical and Experimental Rheumatology|October 18, 2012
Treat-to-target in systemic lupus erythematosus: where are we today?Marta Mosca, Dimitrios T Boumpas, Ian N Bruce, et al.
Journal of Personalized Medicine|July 27, 2024
Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Clinical and Experimental Medicine|March 30, 2024
Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohortStefano Gentileschi, Carla Gaggiano, Arianna Damiani, et al.
Lupus Science & Medicine|October 17, 2023
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for RheumatologyChiara Scirocco, Sara Ferrigno, Laura Andreoli, et al.
Journal of Personalized Medicine|September 28, 2023
ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical PracticeMaurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Clinical and Experimental Rheumatology|August 4, 2017
The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaicNancy Agmon-Levin, Amir Dagan, Yogev Peri, et al.
Pageof 38